Massachusetts Life Sciences Center awards tax incentives to 38 companies to expand and create jobs across Massachusetts
DEVENS — Governor Maura Healey announced nearly $40 million in tax incentives for 38 life sciences companies that are expected to create 1,644 new jobs across Massachusetts.
The awards, made through the Massachusetts Life Sciences Center’s (MLSC) Tax Incentive program, support companies that are expanding their research, development and manufacturing operations in Massachusetts. 31 of the 38 companies receiving awards are expanding outside of Boston and Cambridge and account for 71 percent of the new jobs expected to be created through this round of awards.
Economic Development Secretary Eric Paley joined MLSC Interim President and CEO Liz Graham and local officials to announce the awards at SMC Ltd. in Devens.
“Massachusetts leads the world in life sciences because we invest in the people and companies that are creating the jobs, treatments and technologies of the future,” said Governor Maura Healey. “These investments will help 38 companies grow here in Massachusetts and create more than 1,600 new jobs in communities across our state. We are going to keep competing for jobs, supporting innovation and making sure Massachusetts remains the best place to start and grow a life sciences company.”
“Our life sciences industry supports good jobs and economic growth in communities across Massachusetts,” said Lieutenant Governor Kim Driscoll. “These investments are helping companies expand, hire more workers and continue developing new technologies that can improve people’s lives. We’re proud to support their growth here in Massachusetts.”
The MLSC Tax Incentive program supports life sciences companies engaged in research and development, commercialization and manufacturing in Massachusetts. The program provides incentives to companies of all sizes that commit to creating and retaining new, long-term jobs in the state. Since the Massachusetts Life Sciences Center was established, companies participating in the program have committed to creating more than 22,300 jobs.
“The awards reflect our commitment to scaling life sciences companies here in Massachusetts. These companies reinforce that Massachusetts is the best place to invest, expand, and build for the future,” said Economic Development Secretary Eric Paley, co-chair of the MLSC Board of Directors. “By helping these awardees deepen foundations in the Commonwealth, we’re strengthening our competitive position and supporting sustained growth throughout the industry.”
“The MLSC’s Tax Incentive program is about helping life sciences companies reach the pivotal milestones that will move their innovations forward,” said MLSC Interim President and CEO Liz Graham. “For today’s awardees, that means adding the talent and capabilities needed to advance promising discoveries, bring new technologies closer to patients, and translate innovation into real-world impact.”
“We are honored to be recognized by the Massachusetts Life Sciences Center and appreciate its investment in SMC’s continued growth,” said Chetan N. Patel, CEO and Founder of SMC Ltd. “We are making significant investments in our Devens facility to support new pharmaceutical programs and expand our capabilities. The MLSC award will be a meaningful catalyst for that growth, helping us expand our facility, grow our team, and strengthen SMC’s role as a trusted manufacturing partner for innovative healthcare companies.”
This year’s recipients include companies working in artificial intelligence, women’s health, therapeutics, diagnostics, medical technologies, research and development and biomanufacturing.
The recipients include:
| Company | Expansion Location | Incentive Amount | Job Commitment |
| Alloy Therapeutics Inc. | Waltham | $180,000 | 10 |
| Ardelyx Inc. | Waltham | $277,500 | 15 |
| AstraZeneca Pharmaceuticals LP | Cambridge | $900,000 | 50 |
| Bristol Myers Squibb | Devens | $2,875,000 | 125 |
| CBSET Inc. | Lexington | $660,000 | 33 |
| Cogent Biosciences Inc. | Waltham | $360,000 | 20 |
| Dash Bio Inc. | Waltham | $285,000 | 12 |
| Dyne Therapeutics Inc. | Waltham | $937,500 | 50 |
| Eyepoint Inc. | Northbridge | $1,000,000 | 40 |
| Gentuity LLC | Sudbury | $276,000 | 15 |
| Insulet Corporation | Acton | $10,000,000 | 250 |
| IPG Medical Corporation | Marlborough | $195,000 | 10 |
| Kailera Therapeutics Inc. | Waltham | $900,000 | 50 |
| KalVista Pharmaceuticals Inc. | Framingham | $324,000 | 18 |
| Kymera Therapeutics Inc. | Watertown | $630,000 | 35 |
| Lexington Medical Inc. | Bedford | $180,000 | 10 |
| Lila Sciences Inc. | Cambridge | $3,600,000 | 200 |
| Madrigal Pharmaceuticals Inc. | Waltham | $900,000 | 50 |
| Mercy BioAnalytics Inc. | Waltham | $120,000 | 5 |
| Monte Rosa Therapeutics Inc. | Boston | $720,000 | 40 |
| Nanopath Inc. | Cambridge | $288,000 | 12 |
| Olaris Inc. | Framingham | $125,000 | 5 |
| Pramand LLC | Burlington | $257,500 | 10 |
| Rapport Therapeutics Inc. | Boston | $483,000 | 21 |
| Rentschler Biopharma Inc. | Milford | $517,500 | 23 |
| Repligen Corporation | Marlborough | $415,000 | 20 |
| Rhythm Pharmaceuticals Inc. | Boston | $462,500 | 25 |
| Sanegene Bio USA Inc. | Woburn | $235,000 | 10 |
| SMC Ltd. | Devens | $1,350,000 | 54 |
| Spear Bio Inc. | Woburn | $235,000 | 10 |
| Terrestrial Bio Inc. | Woburn | $1,080,000 | 36 |
| TransMedics Group Inc. | Andover | $1,860,000 | 62 |
| Triveni Bio Inc. | Watertown | $288,000 | 12 |
| Verastem Inc. | Needham | $437,000 | 19 |
| Vericel Corporation | Burlington | $1,100,000 | 50 |
| Vertex Pharmaceuticals Inc. | Boston | $3,025,000 | 121 |
| Werfen | Bedford | $1,303,500 | 66 |
| ZOLL Medical Corporation | Chelmsford | $1,100,000 | 50 |
The MLSC jointly administers the Tax Incentive program with the Massachusetts Department of Revenue, which oversees the technical administration of the incentives. Awardees are required to maintain job commitments over a three-year period. The program includes regular reporting requirements for awardees to document jobs created as a result of the incentive. The MLSC has continued to use the Tax Incentive program to leverage diverse life sciences assets across Massachusetts and encourage growth, expansion, and retention on a statewide basis.
In November 2024, Governor Maura Healey signed the Mass Leads Act, an economic development bill building on the success of the state’s renowned life sciences sector. The legislation increased the statutory cap from $30 million to $40 million for life sciences tax incentives and made targeted reforms to strengthen the program.
Statements of Support:
“Our growth in Waltham reflects the strength of Massachusetts’ life sciences ecosystem,” said Elizabeth Roberts, Chief Human Resources Officer at Alloy Therapeutics. “With support from the MLSC Tax Incentive Program, we’re committed to creating ten new jobs here. We’re grateful for the Commonwealth’s continued investment in the people and companies advancing this work.”
“We are grateful to Governor Healey, Lieutenant Governor Driscoll, and the Massachusetts Life Sciences Center for their continued commitment to the Commonwealth’s life sciences community,” said Mike Raab, President and Chief Executive Officer of Ardelyx. “For emerging and mid-sized biopharmaceutical companies like Ardelyx, targeted incentives like this are especially valuable, helping us create high-quality jobs, compete for talent, and sustain the investment required to translate innovation into new medicines for patients. This program is an excellent example of how government and industry can work together to align incentives that support job creation, scientific innovation, and patient impact. By supporting companies of all sizes, the Healey-Driscoll Administration is helping sustain Massachusetts’ leadership in an industry that is critical to both the Commonwealth’s economy and public health.”
“This tax incentive award comes at a pivotal moment for CBSET as we expand our operations from Lexington to Waltham to meet growing demand from our medical device and biopharma life sciences partners,” said Nathaniel Youndt, Vice President of Commercial Operations at CBSET. “The MLSC’s support allows us to add 33 new jobs and strengthen our role as the translational research partner of choice for companies solving challenges that require deep scientific expertise paired with a committed, lasting engagement. We are grateful for the Healey-Driscoll Administration’s support in ensuring the Commonwealth remains a global life sciences beacon for years to come.”
“Greater Boston has the deepest pool of scientific and engineering talent in the world, and it is why Dash can offer what legacy CROs cannot: lower cost, higher quality, and faster turnaround at the same time,” said Ander Tallett, Co-founder and Chief Operating Officer at Dash Bio. “Our team combines automation and software with GLP-compliant lab operations, so biotech and pharma clients get fixed, published prices plus higher quality. This award supports 12 new jobs in Waltham, and we thank the Massachusetts Life Sciences Center and the Healey-Driscoll Administration for investing in the people who help drug developers reach the clinic sooner.”
“We are grateful to the Massachusetts Life Sciences Center for its support and recognition of Insulet’s continued growth,” said Ashley McEvoy, President and Chief Executive Officer at Insulet. “As we look to the future, this award provides additional flexibility to invest in innovation, expand our capabilities, and advance the next generation of products that help transform the lives of people living with diabetes.”
“This recognition reflects the incredible momentum we’re building at Lila Sciences as we grow our team in Cambridge,” said Mary Jacobs, VP of People at Lila Sciences. “Every person we hire brings us closer to our mission of transforming how scientific discovery happens. We’re proud to be expanding here in Massachusetts, alongside a life sciences community that shares our commitment to pushing the boundaries of what’s possible.”
“We are grateful to the Healey-Driscoll Administration and the Massachusetts Life Sciences Center for supporting Mercy BioAnalytics’ continued growth in Waltham,” said Dawn Mattoon, PhD, Chief Executive Officer of Mercy BioAnalytics. “This award will help us expand our team and advance our mission to transform cancer screening and early detection through innovative blood-based testing.”
“We’re grateful for the continued support of the Massachusetts Life Sciences Center as Nanopath enters our next stage of growth,” said Laney Burke, Associate Director of Business Operations at Nanopath. “We are proud to be based in Cambridge, at the center of one of the world’s leading life sciences ecosystems. This support will help us continue to advance our mission of developing a new class of diagnostics for women’s health.”
“We’re grateful for this support from the Massachusetts Life Sciences Center and Healey-Driscoll Administration. Massachusetts is where Olaris was built, and this award helps us add the scientific talent we need to bring our metabolomic diagnostics to those that need it,” said Elizabeth O’Day, Chief Executive Officer, Chief Scientific Officer, and Founder of Olaris. “Expanding in Massachusetts matters to us.”
“Massachusetts continues to be an exceptional place to build and grow a biotechnology company, with access to world-class talent, research institutions, and an innovation-driven community,” said Hunter Smith, Chief Financial Officer at Rhythm Pharmaceuticals. “We appreciate the support of the MLSC as we expand our team and continue investing in the future of Rhythm.”
“We appreciate the MLSC’s vision and support as we grow our organization in Massachusetts, the best life science ecosystem in the US,” said Marc Abrams, PhD, Chief Technology Officer and Head of US Operations at Sanegene Bio. “We will continue to recruit new talent in 2027 after opening our new, larger US Headquarters in Burlington, MA.”
“Terrestrial Bio is about to open a world-class manufacturing facility and headquarters right in the heart of Boston,” said Rachel Sha, Chief Executive Officer of Terrestrial Bio. “As we lay the foundation for our company’s future, the support we’ve received from the Healey-Driscoll Administration and the MLSC allows us to hire more people, faster. In the years ahead, we look forward to progressing through clinical trials and building a large-scale, successful business right here in Massachusetts.”
“Vericel has a long-standing commitment to Massachusetts, and we are proud to continue growing our workforce and creating highly skilled jobs here in the Commonwealth,” said Joe Mara, Chief Financial Officer at Vericel Corporation. “With the recent completion of our new manufacturing facility and headquarters in Burlington, we are continuing to invest in our people and capabilities as we grow our business and serve more patients who can benefit from our therapies. The MLSC’s support reinforces the strength of Massachusetts’ life sciences ecosystem and helps companies like Vericel continue investing in people, infrastructure and innovation.”
“ZOLL is honored to receive this tax incentive award from the Massachusetts Life Sciences Center,” said Eric Knuden, Chief Executive Officer of ZOLL Medical Corporation. “The award supports our continued investment in Massachusetts, enabling us to expand our workforce, strengthen our R&D and manufacturing capabilities, and advance ZOLL’s lifesaving and life-sustaining technologies. As a company that has operated in Massachusetts for more than 45 years, ZOLL is grateful for MLSC’s partnership, and we look forward to expanding our workforce in the Commonwealth.”
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is a quasi-public economic development investment agency dedicated to supporting the growth and development of the life sciences in Massachusetts, home to the most verdant and productive life sciences ecosystem in the world. Through public-private funding initiatives, the MLSC supports innovation, research and development, commercialization, and manufacturing activities in the fields of biopharma, medical device, diagnostics and digital health. Since 2008, the MLSC has strategically deployed nearly $1.2 billion in Massachusetts, through a combination of grants, loans, capital infrastructure investments, tax incentives and workforce development programs. These investments have created thousands of jobs and propelled the development of new therapies, devices and scientific advancements that are improving patient health and well-being in Massachusetts and beyond.
###
